Loading…
Role of the mouse complement components C5 and C3a in a model of myocardial ischemia and reperfusion injury
Ischemic heart disease is the leading cause of death worldwide. Previous studies have shown that inhibition of C5 is protective in myocardial ischemia and reperfusion (MI/R) injury. However, the role of early complement components upstream from C5 cleavage (e.g., C3a) has not been elucidated. Theref...
Saved in:
Published in: | The FASEB journal 2007-04, Vol.21 (5), p.A12-A12 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Ischemic heart disease is the leading cause of death worldwide. Previous studies have shown that inhibition of C5 is protective in myocardial ischemia and reperfusion (MI/R) injury. However, the role of early complement components upstream from C5 cleavage (e.g., C3a) has not been elucidated. Therefore, we evaluated the role of C5 and C3a in a mouse model of MI/R injury. In wild type mice, MI/R (30 min I and 4 hours of R) induced a significant decrease in ejection fraction, an increase in serum troponin I levels and myocardial neutrophil infiltration. Systemic C5 inhibition with an anti‐C5 monoclonal antibody 30 min prior to R significantly protected mice from MI/R injury. These results confirm an important role for C5 in MI/R injury. Since the C3a receptor antagonist (C3aRA; Calbiochem) induces neutropenia that resolves within 120 min, we administered C3aRA at two different time points in two separate groups. Treatment 30 min prior to R (i.e., within the neutropenic timeframe) protected mice significantly from MI/R injury. Administration 120 min prior to R, when the neutropenia had resolved, but C3aRA was still active, did not prevent mice from MI/R associated injury. These results suggest a minimal role for C3a, since neutropenia rather than C3a receptor antagonism appears to be responsible for C3aRA related amelioration in MI/R injury.
This project was supported by NIH HL56068, HL52886, HL79758 and DE017821. |
---|---|
ISSN: | 0892-6638 1530-6860 |
DOI: | 10.1096/fasebj.21.5.A12-a |